The Salk Institute in San Diego has entered into a multi-year partnership with the cancer research company Indivumed to collect and analyze human cancer tissue, with the goal of turning research into medical applications.
Financial terms of the deal were not disclosed.
Under the agreement, Indivumed will assist Salk Cancer Center researchers in acquiring cancer biospecimens for research. They’ll also collaborate on projects, eyeing a global database of data sets.
“The combination of Indivumed’s molecular and phenotypic data sets with cutting edge basic and translation research coined within the Salk Cancer Center will combine to create one of the world’s most unique research engines,” said Hartmut Juhl, founder and CEO of Indivumed, based in Hamburg, Germany.
Salk billed the deal as “transformational.”
“Indivumed’s controlled and rapid tissue processing will help delineate important biological differences between patient tumors,” said Reuben Shaw, director of the Salk Cancer Center. “Providing our researchers with this type of platinum research resource will have a transformational impact on our research and ultimately our understanding of cancer.”
